Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-PDCD1 / PD-1 / CD279 Reference Antibody (iparomlimab) | Login | Anti-PDCD1 / PD-1 / CD279 Reference Antibody (iparomlimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-TNFRSF5 / CD40 Reference Antibody (ravagalimab) | Login | Anti-TNFRSF5 / CD40 Reference Antibody (ravagalimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB1 / EGFR / HER1 Reference Antibody (SerclutamAb) | Login | Anti-ERBB1 / EGFR / HER1 Reference Antibody (SerclutamAb) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB1 / EGFR / HER1 Reference Antibody (losatuxizumAb) | Login | Anti-ERBB1 / EGFR / HER1 Reference Antibody (losatuxizumAb) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CCR4 / CD194 Reference Antibody (mogamulizumab) | Login | Anti-CCR4 / CD194 Reference Antibody (mogamulizumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-PDCD1 / PD-1 / CD279 Reference Antibody (pidilizumab) | Login | Anti-PDCD1 / PD-1 / CD279 Reference Antibody (pidilizumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab) | Login | Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-PDCD1 / PD-1 / CD279 Reference Antibody (sasanlimab) | Login | Anti-PDCD1 / PD-1 / CD279 Reference Antibody (sasanlimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-PTK7 / CCK4 Reference Antibody (cofetuzumab) | Login | Anti-PTK7 / CCK4 Reference Antibody (cofetuzumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CDH3 / P-cadherin Reference Antibody (PF-03732010) | Login | Anti-CDH3 / P-cadherin Reference Antibody (PF-03732010) | ||||||||||||||||
|
||||||||||||||||||
| Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) | Login | Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (pacmilimab) | Login | Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (pacmilimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-MUC16 Reference Antibody (oregovomab) | Login | Anti-MUC16 Reference Antibody (oregovomab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-NOTCH3 Reference Antibody (tarextumab) | Login | Anti-NOTCH3 Reference Antibody (tarextumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-RSPO3 Reference Antibody (rosmantuzumab) | Login | Anti-RSPO3 Reference Antibody (rosmantuzumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-LY75 / CD205/DEC-205 Reference Antibody (MEN1309) | Login | Anti-LY75 / CD205/DEC-205 Reference Antibody (MEN1309) | ||||||||||||||||
|
||||||||||||||||||
| Anti-HGFR / c-Met Reference Antibody (onartuzumab) | Login | Anti-HGFR / c-Met Reference Antibody (onartuzumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab vedotin) | Login | Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab vedotin) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB2 / HER2 / CD340 Reference Antibody (gancotamab) | Login | Anti-ERBB2 / HER2 / CD340 Reference Antibody (gancotamab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB3 / HER3 Reference Antibody (seribantumab) | Login | Anti-ERBB3 / HER3 Reference Antibody (seribantumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-GUCY2C Reference Antibody (indusatumab vedotin) | Login | Anti-GUCY2C Reference Antibody (indusatumab vedotin) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ICOS / CD278 Reference Antibody (MEDI-570) | Login | Anti-ICOS / CD278 Reference Antibody (MEDI-570) | ||||||||||||||||
|
||||||||||||||||||
| Anti-EphA2 Reference Antibody (MEDI-547) | Login | Anti-EphA2 Reference Antibody (MEDI-547) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ANGPT2 Reference Antibody (MEDI3617) | Login | Anti-ANGPT2 Reference Antibody (MEDI3617) | ||||||||||||||||
|
||||||||||||||||||
| Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (MDX-1105) | Login | Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (MDX-1105) | ||||||||||||||||
|
||||||||||||||||||


